Elucidating the molecular mechanisms underlying mutations in Mycobacterium tuberculosis RNA polymerase that confer resistance to rifampicin and its structural analogues

Varalakshmi Vummidi

doi:10.51248/.v43i4.3453

Authors

Varalakshmi Vummidi

DOI:

https://doi.org/10.51248/.v43i4.3453

Keywords:

Rifampicin, analogs, Mycobacterium tuberculosis, drug resistance, RNA polymerase

Abstract

Tuberculosis (TB) is a major global health problem caused by Mycobacterium tuberculosis (Mtb), and is responsible for significant morbidity and mortality worldwide. Rifampicin and its structural analogues are essential first-line anti-TB drugs that inhibit RNA synthesis by binding to the beta-subunit of Mtb RNA polymerase (RNAP). However, the emergence of rifampicin resistant Mtb strains poses a major challenge for TB control efforts. Mutations in the rpoB gene encoding the beta-subunit of RNAP are the most common cause of rifampicin resistance in Mtb. Understanding the molecular mechanisms underlying these mutations and their effects on RNAP function is crucial for developing new drugs and combination therapies to overcome rifampicin resistance in Mtb. This review discusses the molecular mechanisms underlying rifampicin resistance in Mtb RNAP, including the genetic basis and identification of mutations. It can be hypothesized that rifampicin resistance in Mtb RNAP is a multifactorial phenomenon involving structural, biochemical, and genetic factors. The review highlights strategies for developing new drugs and combination therapies to overcome rifampicin resistance in Mtb and future directions for research on the molecular mechanisms underlying rifampicin resistance in Mtb RNAP.

Author Biography

Varalakshmi Vummidi

Department of Biotechnology, GITAM School of Technology, GITAM, Gandhi Nagar, Rushikonda-530045, Visakhapatnam, Andhra Pradesh, India

References

Li, X., Li, G., Yang, J., Jin, G., Shao, Y., Li, Y., et al., Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2022 Oct 18;23(20):12443.

Zaw, M.T., Emran, N.A., Lin, Z. Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. J Infect Public Health. 2018 Sep-Oct; 11(5):605-610.

Alifano, P., Palumbo, C., Pasanisi, D., Talà, A. Rifampicin-resistance, rpoB polymorphism and RNA polymerase genetic engineering. J Biotechnol. 2015 May 20; 202: 60-77.

Mosaei, H., Harbottle, J. Mechanisms of antibiotics inhibiting bacterial RNA polymerase. Biochem Soc Trans. 2019 Feb 28;47(1):339-350.

Ning, Q., Wang, D., Cheng, F., Zhong, Y., Ding, Q., You, J. Predicting rifampicin resistance mutations in bacterial RNA polymerase subunit beta based on majority consensus. BMC Bioinformatics. 2021 Apr 22;22(1):210.

Xu, G., Liu, H., Jia, X., Wang, X., Xu, P. Mechanisms and detection methods of Mycobacterium tuberculosis rifampicin resistance: The phenomenon of drug resistance is complex. Tuberculosis (Edinb). 2021 May; 128:102083.

Nasiri, M.J., Zamani, S., Pormohammad, A., Feizabadi, M.M., Aslani, H.R., Amin, M., et al., The reliability of rifampicin resistance as a proxy for multidrug-resistant tuberculosis: a systematic review of studies from Iran. Eur J Clin Microbiol Infect Dis. 2018 Jan; 37(1):9-14.

Caminero Luna, J.A., Pérez Mendoza, G., Rodríguez de Castro, F. Multi-drug resistant tuberculosis, ten years later. Med Clin (Barc). 2021 Apr 23;156(8):393-401.

Ahsan, M.J., Ansari, M.Y., Yasmin, S., Jadav, S.S., Kumar, P., Garg, S.K., et al., Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials. Infect Disord Drug Targets. 2015;15(1):32-41.

Conradie, F., Diacon, A.H., Ngubane, N., Howell, P., Everitt, D., Crook, A.M., et al., Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020 Mar 5; 382(10):893-902.

Hewison, C., Khan, U., Bastard, M., Lachenal, N., Coutisson, S., Osso, E., et al., Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort. Clin Infect Dis. 2022 Sep 29;75(6):1006-1013.

Moreno-Molina, M., Shubladze, N., Khurtsilava, I., Avaliani, Z., Bablishvili, N., Torres-Puente, M., et al., Genomic analyses of Mycobacterium tuberculosis from human lung resections reveal a high frequency of polyclonal infections. Nat Commun. 2021 May 11;12(1):2716.

Dean, A.S., Tosas Auguet, O., Glaziou, P., Zignol, M., Ismail, N., Kasaeva, T., et al., 25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward. Lancet Infect Dis. 2022 Jul; 22(7):e 191-e 196.

Singh V, Chibale K. Strategies to Combat Multi-Drug Resistance in Tuberculosis. Acc Chem Res. 2021 May 18;54(10):2361-2376.

Poddar, C.K., Kumari, N., Kumar, R., Shahi, S. K., Kumar, N., Kumar, S. Estimation of genotype MTBDRPLUS line probe assay in detection of rifampicin and isoniazid resistance in comparison to liquid culture (BACTEC-960) drug susceptibility testing in a tertiary care hospital from Eastern India. Biomedicine. 2021 Sep 7;41(2):472-476.

Sannathimmappa, M., Parameshwara, P. G., Aravindakshan, R., Nambiar, V. Global scenario and recent advances in molecular diagnosis and management of drug-resistant tuberculosis. Biomedicine. 2021 Oct 29;41(3):522-530.

Miotto, P., Zhang, Y., Cirillo, D.M., Yam, W.C. Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology. 2018 Dec;23(12):1098-1113.

Sheikh, B.A., Bhat, B.A., Ahmad, Z., Mir MA. Strategies Employed to Evade the Host Immune Response and the Mechanism of Drug Resistance in Mycobacterium tuberculosis: In Search of Finding New Targets. Curr Pharm Biotechnol. 2022; 23(14):1704-1720.

(Liebenberg, D., Gordhan, B.G., Kana, B.D. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Front Cell Infect Microbiol. 2022 Sep 23;12:943545.

Al-Ghafli, H., Al-Hajoj, S. Clinical Management of Drug-resistant Mycobacterium tuberculosis Strains: Pathogen-targeted Versus Host-directed Treatment Approaches. Curr Pharm Biotechnol. 2019;20(4):272-284.

Gupta, V.K., Kumar, M.M., Singh, D., Bisht, D., Sharma, S. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality? Infect Dis (Lond). 2018 Feb;50(2):81-94.

Sundararajan, S., Muniyan, R. Latent tuberculosis: interaction of virulence factors in Mycobacterium tuberculosis. Mol Biol Rep. 2021 Aug;48(8):6181-6196.

Modlin, S.J., Elghraoui, A., Gunasekaran, D., Zlotnicki, A.M., Dillon, N.A., Dhillon, N., et al., Structure-Aware Mycobacterium tuberculosis Functional Annotation Uncloaks Resistance, Metabolic, and Virulence Genes. mSystems. 2021 Dec 21;6(6):e0067321.

Chakraborty, P., Bajeli, S., Kaushal, D., Radotra, B.D., Kumar, A. Biofilm formation in the lung contributes to virulence and drug tolerance of Mycobacterium tuberculosis. Nat Commun. 2021 Mar 11;12(1):1606.

Anderson, A.C., Wright, D.L. The challenge of resistance in antimicrobial drug development. Future Microbiol. 2015;10(11):1709-1710.